Riley Myers

FDA investigator · also recorded as Peter Riley C. Myers, Ae Rla- Riley Myers

Appears on 7 documents from 2018 to 2022, most often at sites in California. Most often cites written procedures; deviations (21 CFR 211.100).

7
Documents on file
4.5
Observations per 483
2018
First seen
2022
Most recent

What they cite most

From 43 observations

Activity by year

2018: 1, 2019: 2, 2021: 1, 2022: 3

Where

California 1 · Denmark 1 · Illinois 1 · Puerto Rico 1 · Singapore 1 · South Korea 1

Is Riley Myers coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

7 documents, newest first
FirmOpen
483 Roche Singapore Technical Operations Pte. Ltd.Aug 1, 2022 · Singapore, Singapore
483 Genentech, Inc.May 26, 2022 · South San Francisco, California
483 Kashiv BioSciences, LLCJan 14, 2022 · Chicago, Illinois
483 AGC Biologics, Inc.Mar 19, 2021 · Bothell, Washington
483 AGC Biologics A/SNov 5, 2019 · Soeborg, Denmark
483 Amgen Manufacturing Limited LLCMay 8, 2019 · Juncos, Puerto Rico
483 Samsung Biologics Co., Ltd.Mar 14, 2018 · Incheon, South Korea

About this profile

What does Riley Myers inspect?

Riley Myers appears on 7 documents on file covering 7 sites, most often in California.

What do they cite most often?

21 CFR 211.100 (written procedures; deviations), followed by 21 CFR 211.192 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Riley Myers is dated Aug 1, 2022.